argenex SE $ARGX Stock Sold by Crossmark Global Holdings Inc.

Key Points

• Crossmark Global Holdings cut its argenx position by 22.9% in the third quarter, selling 2,218 shares and retaining 7,466 shares valued at approximately $7.16 million. Institutional investors collectively own 60.32% of ARGX.
• Analysts remain broadly bullish: argenx has a consensus “Moderate Buy” rating and an average price target of $1,148, with recent targets ranging from $1,038 to $1,356.
• argenx reported quarterly EPS of $7.80, beating estimates of $7.44, on revenue of $1.75 billion. Shares opened at $875.76, compared with a 52-week range of $661.85 to $1,072.75.

Crossmark Global Holdings Inc. decreased its position in shares of argenex SE (NASDAQ:ARGX - Free Report) by 22.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,466 shares of the company's stock after selling 2,218 shares during the period. Crossmark Global Holdings Inc.'s holdings in argenex were worth $7,159,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of ARGX. Eastern Bank bought a new position in shares of argenex in the second quarter valued at approximately $32,000. Whipplewood Advisors LLC acquired a new position in shares of argenex in the 1st quarter worth approximately $28,000. Axiom Investment Management LLC bought a new stake in argenex during the 1st quarter worth approximately $50,000. Mather Group LLC. grew its position in argenex by 19.1% during the 3rd quarter. Mather Group LLC. now owns 81 shares of the company's stock worth $78,000 after acquiring an additional 13 shares during the last quarter. Finally, WPG Advisers LLC grew its position in argenex by 17.8% during the 1st quarter. WPG Advisers LLC now owns 86 shares of the company's stock worth $63,000 after acquiring an additional 13 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

Analysts Set New Price Targets

ARGX has been the subject of a number of recent analyst reports. The Goldman Sachs Group reaffirmed a "buy" rating on shares of argenex in a report on Friday, September 25th. Oppenheimer reduced their price objective on argenex from $1,100.00 to $1,038.00 and set an "outperform" rating on the stock in a research note on Monday, October 12th. Citizens Jmp boosted their price objective on argenex from $932.00 to $1,200.00 and gave the stock a "market outperform" rating in a research note on Tuesday, August 18th. Wells Fargo & Company increased their target price on argenex from $1,355.00 to $1,356.00 and gave the stock an "overweight" rating in a report on Wednesday, October 14th. Finally, Morgan Stanley raised their target price on argenex from $1,230.00 to $1,250.00 and gave the company an "overweight" rating in a research note on Monday, August 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $1,148.00.

argenex Stock Performance

Shares of ARGX opened at $875.76 on Friday. The business's fifty day moving average price is $956.17 and its two-hundred day moving average price is $885.45. The firm has a market capitalization of $55.08 billion, a price-to-earnings ratio of 33.63, a PEG ratio of 0.82 and a beta of 0.44. argenex SE has a 52 week low of $661.85 and a 52 week high of $1,072.75.

argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings data on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping analysts' consensus estimates of $7.44 by $0.36. argenex had a return on equity of 43.59% and a net margin of 32.19%. The firm had revenue of $1.75 billion during the quarter. As a group, research analysts forecast that argenex SE will post 28.71 EPS for the current year.

About argenex

argenx SE NASDAQ: ARGX is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx's lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.